Literature DB >> 8093821

Persistent tardive dyskinesia: demographic and pharmacological risk factors.

G Muscettola1, S Pampallona, G Barbato, M Casiello, P Bollini.   

Abstract

The demographic, clinical and pharmacological risk factors for persistent tardive dyskinesia (TD) were investigated in a sample of 1745 patients. When simultaneously adjusting for the effects of demographic and pharmacological factors using multivariate logistic regression, female sex and advanced age were positively and significantly associated with increased risk of TD. Interaction between these two variables, investigated by cross-stratification, was significant. Furthermore, high neuroleptic dose and concomitant use of neuroleptic and antiparkinsonian drugs were both significantly associated with increased risk of TD. The results support the view that both vulnerability factors and high neuroleptic doses contribute to the occurrence of TD and further stress the relevance of a conservative use of antipsychotic medication, particularly in older women.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8093821     DOI: 10.1111/j.1600-0447.1993.tb03326.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  5 in total

Review 1.  Drug-induced movement disorders.

Authors:  F J Jiménez-Jiménez; P J García-Ruiz; J A Molina
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

2.  Basal ganglia abnormalities in tardive dyskinesia. Possible relationship with duration of neuroleptic treatment.

Authors:  P Dalgalarrondo; W F Gattaz
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

3.  Managing antipsychotic-induced acute and tardive dystonia.

Authors:  M Raja
Journal:  Drug Saf       Date:  1998-07       Impact factor: 5.606

4.  Chiropractic management of musculoskeletal pain secondary to tardive dyskinesia.

Authors:  Kelly Schoonderwoerd
Journal:  J Can Chiropr Assoc       Date:  2005-06

5.  The relationship between motor effects in rats following acute and chronic haloperidol treatment.

Authors:  H A Jørgensen; O A Andreassen; K Hole
Journal:  Psychopharmacology (Berl)       Date:  1994-09       Impact factor: 4.530

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.